Document is current

Article History

Received: 28 October 2021

Revised: 20 May 2022

Accepted: 26 May 2022

First Online: 22 August 2022

Declarations

:

: Christopher P. Bridge receives research funding from GE Healthcare, Nvidia Corporation, and Bayer, AG. Steven Pieper is in part supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) (P41 EB015902) and by the National Cancer Institute, National Institutes of Health, under Task Order No. HHSN26110071 under Contract No. HHSN261201500003l. Jayashree Kalpathy-Cramer is in part supported by the National Cancer Institute CI U01CA242879, and receives research funding from GE Healthcare, Genentech, Inc, and Bayer, AG. Andriy Y. Fedorov is in part supported by the National Institute of Biomedical Imaging and Bioengineering: contracts 75N92020C00008 and 75N92020C00021; grant P41 EB028741, and by the National Cancer Institute: Task Order No. HHSN26110071 under Contract No. HHSN261201500003l; grants U24 CA264044 and R01 CA241817. David A. Clunie receives financial compensation as a consultant of Philips Algotec, as a consultant for Essex Leidos CBIIT NCI, as a consultant for Brigham and Women’s Hospital NCI Imaging Data Commons (IDC), as a consultant for the University of Leeds Northern Pathology Imaging Co-operative (NPIC), and as a contractor for NEMA as DICOM Editor. Markus D. Herrmann is in part supported by the National Cancer Institute: Task Order No. HHSN26110071 under Contract No. HHSN2612015000031. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.